Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures
R. Vander Velde, N. Yoon, V. Marusyk, A. Durmaz, A. Dhawan, D. Myroshnychenko, D. Peral, B. Desai, O. Balynska, J. Poleszhuk, K. Liu, M. Abazeed, A. C. Tan, O. Mian, E. Haura, , A. Marusyk
The paper investigates resistance to ALK inhibitors in NSCLC, finding that resistance develops through gradual, multifactorial genetic and epigenetic changes rather than single mutations or reprogramming.
bioRxiv · Nov 19, 2019Cancer Biology